Evaluating Inflammatory Joint Pain in Older Adults Lee, Levinson, and Makris have published an approach to evaluating inflammatory joint pain in older adults in JAMA Internal Medicine. While intended to be a practical guide for Primary Care Clinicians (PCCs), the tenets and https://t.co/TPKEOjkcKl

Wealth and Where you Live Influences Outcomes Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and https://t.co/MyzWRx580R

Survey: Upgrading & Maximizing the Classics (Urate Lowering Therapies, etc) https://t.co/w6uzIlaeG7 https://t.co/HW09DVrMed

What's New in Lyme Disease JAMA has published an overview of new considerations on Lyme disease, focusing on Diagnostics, Vaccines, and Prevention. https://t.co/jG09wc6gI8 https://t.co/rQBW6RIz5U

"Be so good they can't ignore you." - Steve Martin https://t.co/lMRAY57rW9

POETYK PsA-1: Deucravacitinib in Biologic-Naïve PsA POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in PsA patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, https://t.co/VjwpCVKPz0

Study of 364 Japanese myositis (IIM) pts - 42 (11.4%) had cancer-assoc myositis (CAM); 30/42 Dx w/in ±1 yr of IIM. CA risk incr ±3 yrs of IIM (SIR 2.54), highest 1st yr (SIR 8.66). 5 factors predicted CAM: TIF1γ +, ^CRP, dermatomyositis, older age, +FHx CA (AUC 0.86; sensitivity https://t.co/9ojTWTK5kO

Congratulations to Dr. Edoardo Cipolletta (U Nottingham) - winner of Gout, Urate, and Crystal Deposition Disease Best PhD Thesis Award. Read his insightful interview on his reasearch on #gout. https://t.co/5i3hEV6PJX https://t.co/XV5trvEonW

Substudy of 131 Still’s dz pts from the Autoinflammatory Dz (AIDA) registry. 38% underdosed w/ canakinumab (CAN) vs 62% appropriately dosed (300 mg q4wks or 4 mg/kg). Underdosed CAN had lower odds of long-term remission & D/C CAN (3.9% vs 19%) https://t.co/l94zB9NkKv https://t.co/D8FNUXS0nv

CDC warns of an association betw severe CNS arboviral disease, w/ neurologic sequelae in pts receiving anti-CD20 mAbs (rituximab, ocrelizumab, ofatumumab, obinutuzumab, etc). West Nile virus was the most common arbovirus, but there are others; mortality up to 40%. Most arbovirus https://t.co/WWg41fsRgr

From 1975 -2025, incidence of Kawasaki dz (KD) increased 16.1-fold in Japan, KD cases 15 032 and& 14 809 in 2023 & 2024, but during COVID #s dropped to 10 333 in 2022. KD #s rebounded after the COVID-19: Infants showed minimal changes, but kids 5-9 had the greatest increase https://t.co/j0BL2ZELXn

Simple infographic on the MOA of deucravacitinib (Sotyktu). https://t.co/fXbxMAzvAE https://t.co/6IvA0Xz3m2

MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG

NP Salaries: in 7 specialties, NPs now avg >$150,000/yr, with the avg annual salary surpassing $137,000 in 2026 according toBureau of Labor Statistics. https://t.co/LlGFxkvEj5 https://t.co/h5bKsrnm4k

Multimodal & multidisciplinary Tx (MMT) are underutilized in adults w/ chronic pain. Study of 347 Chr pain pts - 60% used non-opioid meds; 29% used opioids & only 11% MMT. Older age & high intensity pain assoc w/ Opioids. MMT had more complex pain w/ greater pain interference, https://t.co/iF0UQeut9b